ID   AAAD_HUMAN              Reviewed;         399 AA.
AC   P22760; A8K3L3; D3DNJ6; Q8N1A9;
DT   01-AUG-1991, integrated into UniProtKB/Swiss-Prot.
DT   11-JAN-2011, sequence version 5.
DT   10-MAY-2017, entry version 158.
DE   RecName: Full=Arylacetamide deacetylase;
DE            EC=3.1.1.3;
GN   Name=AADAC; Synonyms=DAC;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], PARTIAL PROTEIN SEQUENCE, AND VARIANT
RP   ILE-281.
RC   TISSUE=Liver;
RX   PubMed=8063807;
RA   Probst M.R., Beer M., Beer D., Jenoe P., Meyer U.A., Gasser R.;
RT   "Human liver arylacetamide deacetylase. Molecular cloning of a novel
RT   esterase involved in the metabolic activation of arylamine carcinogens
RT   with high sequence similarity to hormone-sensitive lipase.";
RL   J. Biol. Chem. 269:21650-21656(1994).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANT ILE-281.
RC   TISSUE=Heart;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16641997; DOI=10.1038/nature04728;
RA   Muzny D.M., Scherer S.E., Kaul R., Wang J., Yu J., Sudbrak R.,
RA   Buhay C.J., Chen R., Cree A., Ding Y., Dugan-Rocha S., Gill R.,
RA   Gunaratne P., Harris R.A., Hawes A.C., Hernandez J., Hodgson A.V.,
RA   Hume J., Jackson A., Khan Z.M., Kovar-Smith C., Lewis L.R.,
RA   Lozado R.J., Metzker M.L., Milosavljevic A., Miner G.R., Morgan M.B.,
RA   Nazareth L.V., Scott G., Sodergren E., Song X.-Z., Steffen D., Wei S.,
RA   Wheeler D.A., Wright M.W., Worley K.C., Yuan Y., Zhang Z., Adams C.Q.,
RA   Ansari-Lari M.A., Ayele M., Brown M.J., Chen G., Chen Z.,
RA   Clendenning J., Clerc-Blankenburg K.P., Chen R., Chen Z., Davis C.,
RA   Delgado O., Dinh H.H., Dong W., Draper H., Ernst S., Fu G.,
RA   Gonzalez-Garay M.L., Garcia D.K., Gillett W., Gu J., Hao B.,
RA   Haugen E., Havlak P., He X., Hennig S., Hu S., Huang W., Jackson L.R.,
RA   Jacob L.S., Kelly S.H., Kube M., Levy R., Li Z., Liu B., Liu J.,
RA   Liu W., Lu J., Maheshwari M., Nguyen B.-V., Okwuonu G.O., Palmeiri A.,
RA   Pasternak S., Perez L.M., Phelps K.A., Plopper F.J., Qiang B.,
RA   Raymond C., Rodriguez R., Saenphimmachak C., Santibanez J., Shen H.,
RA   Shen Y., Subramanian S., Tabor P.E., Verduzco D., Waldron L., Wang J.,
RA   Wang J., Wang Q., Williams G.A., Wong G.K.-S., Yao Z., Zhang J.,
RA   Zhang X., Zhao G., Zhou J., Zhou Y., Nelson D., Lehrach H.,
RA   Reinhardt R., Naylor S.L., Yang H., Olson M., Weinstock G.,
RA   Gibbs R.A.;
RT   "The DNA sequence, annotation and analysis of human chromosome 3.";
RL   Nature 440:1194-1198(2006).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA], AND VARIANT ILE-281.
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Colon;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   PARTIAL PROTEIN SEQUENCE, AND CHARACTERIZATION.
RC   TISSUE=Liver;
RX   PubMed=2043131; DOI=10.1016/0006-291X(91)92005-5;
RA   Probst M.R., Jenoe P., Meyer U.A.;
RT   "Purification and characterization of a human liver arylacetamide
RT   deacetylase.";
RL   Biochem. Biophys. Res. Commun. 177:453-459(1991).
RN   [7]
RP   FUNCTION.
RX   PubMed=17936933; DOI=10.1002/jbt.20178;
RA   Ross M.K., Crow J.A.;
RT   "Human carboxylesterases and their role in xenobiotic and endobiotic
RT   metabolism.";
RL   J. Biochem. Mol. Toxicol. 21:187-196(2007).
RN   [8]
RP   FUNCTION, TISSUE SPECIFICITY, SUBCELLULAR LOCATION, AND
RP   BIOPHYSICOCHEMICAL PROPERTIES.
RX   PubMed=19339378; DOI=10.1124/dmd.109.026567;
RA   Watanabe A., Fukami T., Nakajima M., Takamiya M., Aoki Y., Yokoi T.;
RT   "Human arylacetamide deacetylase is a principal enzyme in flutamide
RT   hydrolysis.";
RL   Drug Metab. Dispos. 37:1513-1520(2009).
RN   [9]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-78 AND ASN-282.
RC   TISSUE=Liver;
RX   PubMed=19159218; DOI=10.1021/pr8008012;
RA   Chen R., Jiang X., Sun D., Han G., Wang F., Ye M., Wang L., Zou H.;
RT   "Glycoproteomics analysis of human liver tissue by combination of
RT   multiple enzyme digestion and hydrazide chemistry.";
RL   J. Proteome Res. 8:651-661(2009).
RN   [10]
RP   BIOPHYSICOCHEMICAL PROPERTIES, FUNCTION, AND TISSUE SPECIFICITY.
RX   PubMed=22207054; DOI=10.1124/dmd.111.043067;
RA   Kobayashi Y., Fukami T., Nakajima A., Watanabe A., Nakajima M.,
RA   Yokoi T.;
RT   "Species differences in tissue distribution and enzyme activities of
RT   arylacetamide deacetylase in human, rat, and mouse.";
RL   Drug Metab. Dispos. 40:671-679(2012).
RN   [11]
RP   FUNCTION, SUBCELLULAR LOCATION, TISSUE SPECIFICITY, BIOPHYSICOCHEMICAL
RP   PROPERTIES, VARIANTS ILE-281 AND GLN-399 EXT, AND CHARACTERIZATION OF
RP   VARIANTS ILE-281 AND GLN-399 EXT.
RX   PubMed=22415931; DOI=10.1124/dmd.112.044883;
RA   Shimizu M., Fukami T., Kobayashi Y., Takamiya M., Aoki Y.,
RA   Nakajima M., Yokoi T.;
RT   "A novel polymorphic allele of human arylacetamide deacetylase leads
RT   to decreased enzyme activity.";
RL   Drug Metab. Dispos. 40:1183-1190(2012).
RN   [12]
RP   BIOPHYSICOCHEMICAL PROPERTIES, GLYCOSYLATION AT ASN-78 AND ASN-282,
RP   AND MUTAGENESIS OF ASN-78 AND ASN-282.
RX   PubMed=24125761; DOI=10.1016/j.bcp.2013.10.001;
RA   Muta K., Fukami T., Nakajima M., Yokoi T.;
RT   "N-Glycosylation during translation is essential for human
RT   arylacetamide deacetylase enzyme activity.";
RL   Biochem. Pharmacol. 87:352-359(2014).
RN   [13]
RP   FUNCTION, AND INDUCTION.
RX   PubMed=23542347; DOI=10.1016/j.jhep.2013.03.022;
RA   Nourbakhsh M., Douglas D.N., Pu C.H., Lewis J.T., Kawahara T.,
RA   Lisboa L.F., Wei E., Asthana S., Quiroga A.D., Law L.M., Chen C.,
RA   Addison W.R., Nelson R., Houghton M., Lehner R., Kneteman N.M.;
RT   "Arylacetamide deacetylase: a novel host factor with important roles
RT   in the lipolysis of cellular triacylglycerol stores, VLDL assembly and
RT   HCV production.";
RL   J. Hepatol. 59:336-343(2013).
RN   [14]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [15]
RP   VARIANT ILE-281.
RX   PubMed=12721789; DOI=10.1007/s10038-003-0021-7;
RA   Saito S., Iida A., Sekine A., Kawauchi S., Higuchi S., Ogawa C.,
RA   Nakamura Y.;
RT   "Catalog of 680 variations among eight cytochrome p450 (CYP) genes,
RT   nine esterase genes, and two other genes in the Japanese population.";
RL   J. Hum. Genet. 48:249-270(2003).
CC   -!- FUNCTION: Displays cellular triglyceride lipase activity in liver,
CC       increases the levels of intracellular fatty acids derived from the
CC       hydrolysis of newly formed triglyceride stores and plays a role in
CC       very low-density lipoprotein assembly. Displays serine esterase
CC       activity in liver. Deacetylates a variety of arylacetamide
CC       substrates, including xenobiotic compounds and procarcinogens,
CC       converting them to the primary arylamide compounds and increasing
CC       their toxicity. {ECO:0000269|PubMed:17936933,
CC       ECO:0000269|PubMed:19339378, ECO:0000269|PubMed:22207054,
CC       ECO:0000269|PubMed:22415931, ECO:0000269|PubMed:23542347}.
CC   -!- CATALYTIC ACTIVITY: Triacylglycerol + H(2)O = diacylglycerol + a
CC       carboxylate.
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=0.8 mM for flutamide {ECO:0000269|PubMed:19339378,
CC         ECO:0000269|PubMed:22207054, ECO:0000269|PubMed:22415931,
CC         ECO:0000269|PubMed:24125761};
CC         KM=0.6 mM for flutamide {ECO:0000269|PubMed:19339378,
CC         ECO:0000269|PubMed:22207054, ECO:0000269|PubMed:22415931,
CC         ECO:0000269|PubMed:24125761};
CC         KM=0.472 mM for flutamide {ECO:0000269|PubMed:19339378,
CC         ECO:0000269|PubMed:22207054, ECO:0000269|PubMed:22415931,
CC         ECO:0000269|PubMed:24125761};
CC         KM=3.05 mM for phenacetin {ECO:0000269|PubMed:19339378,
CC         ECO:0000269|PubMed:22207054, ECO:0000269|PubMed:22415931,
CC         ECO:0000269|PubMed:24125761};
CC         KM=1.8 mM for phenacetin {ECO:0000269|PubMed:19339378,
CC         ECO:0000269|PubMed:22207054, ECO:0000269|PubMed:22415931,
CC         ECO:0000269|PubMed:24125761};
CC         KM=1.42 mM for phenacetin {ECO:0000269|PubMed:19339378,
CC         ECO:0000269|PubMed:22207054, ECO:0000269|PubMed:22415931,
CC         ECO:0000269|PubMed:24125761};
CC         KM=0.2 mM for rifampicin {ECO:0000269|PubMed:19339378,
CC         ECO:0000269|PubMed:22207054, ECO:0000269|PubMed:22415931,
CC         ECO:0000269|PubMed:24125761};
CC         KM=0.154 mM for rifampicin {ECO:0000269|PubMed:19339378,
CC         ECO:0000269|PubMed:22207054, ECO:0000269|PubMed:22415931,
CC         ECO:0000269|PubMed:24125761};
CC         Vmax=1.1 nmol/min/mg enzyme toward flutamide
CC         {ECO:0000269|PubMed:19339378, ECO:0000269|PubMed:22207054,
CC         ECO:0000269|PubMed:22415931, ECO:0000269|PubMed:24125761};
CC         Vmax=0.617 nmol/min/mg enzyme toward flutamide
CC         {ECO:0000269|PubMed:19339378, ECO:0000269|PubMed:22207054,
CC         ECO:0000269|PubMed:22415931, ECO:0000269|PubMed:24125761};
CC         Vmax=1.34 nmol/min/mg enzyme toward phenacetin
CC         {ECO:0000269|PubMed:19339378, ECO:0000269|PubMed:22207054,
CC         ECO:0000269|PubMed:22415931, ECO:0000269|PubMed:24125761};
CC         Vmax=6.4 nmol/min/mg enzyme toward phenacetin
CC         {ECO:0000269|PubMed:19339378, ECO:0000269|PubMed:22207054,
CC         ECO:0000269|PubMed:22415931, ECO:0000269|PubMed:24125761};
CC         Vmax=1.42 nmol/min/mg enzyme toward phenacetin
CC         {ECO:0000269|PubMed:19339378, ECO:0000269|PubMed:22207054,
CC         ECO:0000269|PubMed:22415931, ECO:0000269|PubMed:24125761};
CC         Vmax=0.149 nmol/min/mg enzyme toward rifampicin
CC         {ECO:0000269|PubMed:19339378, ECO:0000269|PubMed:22207054,
CC         ECO:0000269|PubMed:22415931, ECO:0000269|PubMed:24125761};
CC         Vmax=0.060 nmol/min/mg enzyme toward rifampicin
CC         {ECO:0000269|PubMed:19339378, ECO:0000269|PubMed:22207054,
CC         ECO:0000269|PubMed:22415931, ECO:0000269|PubMed:24125761};
CC   -!- SUBCELLULAR LOCATION: Endoplasmic reticulum membrane; Single-pass
CC       type II membrane protein. Microsome membrane; Single-pass type II
CC       membrane protein.
CC   -!- TISSUE SPECIFICITY: Detected in liver (at protein level). Mainly
CC       expressed in liver, small intestine, colon, adrenal gland and
CC       bladder. {ECO:0000269|PubMed:19339378,
CC       ECO:0000269|PubMed:22207054, ECO:0000269|PubMed:22415931}.
CC   -!- INDUCTION: Down-regulated following infection with hepatis C virus
CC       which results in impaired triacylglycerol lipolysis and impaired
CC       assembly of very low density lipoproteins. This may represent a
CC       cellular adaptation to infection that is aimed at limiting viral
CC       production. {ECO:0000269|PubMed:23542347}.
CC   -!- PTM: Glycosylation is required for enzyme activity.
CC       {ECO:0000269|PubMed:19159218, ECO:0000269|PubMed:24125761}.
CC   -!- POLYMORPHISM: Three alleles are known: AADAC*1, AADAC*2 and
CC       AADAC*3. The sequence shown is that of AADAC*1 which is found in
CC       European American, African American, Japanese and Korean
CC       populations at allelic frequencies of 39.3 to 47.4%. The AADAC*2
CC       allele is found in European American, African American, Korean,
CC       and Japanese populations at allelic frequencies of 52.6 to 63.5%
CC       whereas the AADAC*3 allele is found in European American (1.3%)
CC       and African American (2.0%) samples but not in Japanese or Korean
CC       samples. {ECO:0000269|PubMed:22415931}.
CC   -!- MISCELLANEOUS: Can hydrolyze a number of clinical drugs such as
CC       flutamide, an antiandrogen drug used for the treatment of prostate
CC       cancer; phenacetin, an analgesic antipyretic which has been
CC       withdrawn from the market due to its links with renal failure; and
CC       rifamycins which have been used as antituberculosis drugs.
CC   -!- SIMILARITY: Belongs to the 'GDXG' lipolytic enzyme family.
CC       {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAA35551.1; Type=Frameshift; Positions=53, 56; Evidence={ECO:0000305};
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; L32179; AAA35551.1; ALT_FRAME; mRNA.
DR   EMBL; AK290628; BAF83317.1; -; mRNA.
DR   EMBL; AC068647; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471052; EAW78791.1; -; Genomic_DNA.
DR   EMBL; CH471052; EAW78792.1; -; Genomic_DNA.
DR   EMBL; BC032309; AAH32309.1; -; mRNA.
DR   CCDS; CCDS33877.1; -.
DR   PIR; A53856; A53856.
DR   RefSeq; NP_001077.2; NM_001086.2.
DR   UniGene; Hs.506908; -.
DR   ProteinModelPortal; P22760; -.
DR   IntAct; P22760; 1.
DR   STRING; 9606.ENSP00000232892; -.
DR   BindingDB; P22760; -.
DR   ChEMBL; CHEMBL3509584; -.
DR   ESTHER; human-AADAC; Hormone-sensitive_lipase_like_1.
DR   MEROPS; S09.991; -.
DR   iPTMnet; P22760; -.
DR   PhosphoSitePlus; P22760; -.
DR   BioMuta; AADAC; -.
DR   DMDM; 317373587; -.
DR   PaxDb; P22760; -.
DR   PeptideAtlas; P22760; -.
DR   PRIDE; P22760; -.
DR   Ensembl; ENST00000232892; ENSP00000232892; ENSG00000114771.
DR   GeneID; 13; -.
DR   KEGG; hsa:13; -.
DR   UCSC; uc003eze.4; human.
DR   CTD; 13; -.
DR   DisGeNET; 13; -.
DR   GeneCards; AADAC; -.
DR   HGNC; HGNC:17; AADAC.
DR   HPA; HPA002911; -.
DR   MIM; 600338; gene.
DR   neXtProt; NX_P22760; -.
DR   OpenTargets; ENSG00000114771; -.
DR   PharmGKB; PA24363; -.
DR   eggNOG; KOG1515; Eukaryota.
DR   eggNOG; COG0657; LUCA.
DR   GeneTree; ENSGT00550000074556; -.
DR   HOGENOM; HOG000033738; -.
DR   HOVERGEN; HBG058974; -.
DR   InParanoid; P22760; -.
DR   KO; K13616; -.
DR   OMA; RENAHYP; -.
DR   OrthoDB; EOG091G082E; -.
DR   PhylomeDB; P22760; -.
DR   TreeFam; TF314978; -.
DR   Reactome; R-HSA-211945; Phase 1 - Functionalization of compounds.
DR   SABIO-RK; P22760; -.
DR   GeneWiki; AADAC; -.
DR   GenomeRNAi; 13; -.
DR   PRO; PR:P22760; -.
DR   Proteomes; UP000005640; Chromosome 3.
DR   Bgee; ENSG00000114771; -.
DR   CleanEx; HS_AADAC; -.
DR   ExpressionAtlas; P22760; baseline and differential.
DR   Genevisible; P22760; HS.
DR   GO; GO:0005789; C:endoplasmic reticulum membrane; IDA:UniProtKB.
DR   GO; GO:0016021; C:integral component of membrane; IEA:UniProtKB-KW.
DR   GO; GO:0031090; C:organelle membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0003824; F:catalytic activity; TAS:ProtInc.
DR   GO; GO:0019213; F:deacetylase activity; IDA:UniProtKB.
DR   GO; GO:0016298; F:lipase activity; TAS:UniProtKB.
DR   GO; GO:0017171; F:serine hydrolase activity; IDA:UniProtKB.
DR   GO; GO:0004806; F:triglyceride lipase activity; ISS:UniProtKB.
DR   GO; GO:0009056; P:catabolic process; IBA:GO_Central.
DR   GO; GO:0010898; P:positive regulation of triglyceride catabolic process; ISS:UniProtKB.
DR   GO; GO:0006805; P:xenobiotic metabolic process; TAS:Reactome.
DR   Gene3D; 3.40.50.1820; -; 1.
DR   InterPro; IPR029058; AB_hydrolase.
DR   InterPro; IPR013094; AB_hydrolase_3.
DR   InterPro; IPR017157; Arylacetamide_deacetylase.
DR   InterPro; IPR033140; Lipase_GDXG_put_SER_AS.
DR   Pfam; PF07859; Abhydrolase_3; 2.
DR   PIRSF; PIRSF037251; Arylacetamide_deacetylase; 1.
DR   SUPFAM; SSF53474; SSF53474; 1.
DR   PROSITE; PS01174; LIPASE_GDXG_SER; 1.
PE   1: Evidence at protein level;
KW   Complete proteome; Direct protein sequencing; Disulfide bond;
KW   Endoplasmic reticulum; Glycoprotein; Hydrolase; Membrane; Microsome;
KW   Polymorphism; Reference proteome; Signal-anchor; Transmembrane;
KW   Transmembrane helix.
FT   CHAIN         1    399       Arylacetamide deacetylase.
FT                                /FTId=PRO_0000071542.
FT   TOPO_DOM      1      5       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM      6     23       Helical; Signal-anchor for type II
FT                                membrane protein. {ECO:0000255}.
FT   TOPO_DOM     24    399       Lumenal. {ECO:0000255}.
FT   MOTIF       111    113       Involved in the stabilization of the
FT                                negatively charged intermediate by the
FT                                formation of the oxyanion hole.
FT                                {ECO:0000250|UniProtKB:Q5NUF3}.
FT   ACT_SITE    189    189       {ECO:0000250|UniProtKB:Q8BLF1,
FT                                ECO:0000255|PROSITE-ProRule:PRU10038}.
FT   ACT_SITE    343    343       {ECO:0000250|UniProtKB:Q8BLF1}.
FT   ACT_SITE    373    373       {ECO:0000250|UniProtKB:Q8BLF1}.
FT   CARBOHYD     78     78       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000269|PubMed:19159218,
FT                                ECO:0000269|PubMed:24125761}.
FT   CARBOHYD    282    282       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000269|PubMed:19159218,
FT                                ECO:0000269|PubMed:24125761}.
FT   DISULFID    116    340       {ECO:0000250}.
FT   VARIANT     281    281       V -> I (in alleles AADAC*2 and AADAC*3;
FT                                mildly decreased enzyme activity;
FT                                dbSNP:rs1803155).
FT                                {ECO:0000269|PubMed:12721789,
FT                                ECO:0000269|PubMed:14702039,
FT                                ECO:0000269|PubMed:22415931,
FT                                ECO:0000269|PubMed:8063807,
FT                                ECO:0000269|Ref.4}.
FT                                /FTId=VAR_014798.
FT   VARIANT     399    399       L -> LQ (in allele AADAC*3; decreased
FT                                enzyme activity).
FT                                {ECO:0000269|PubMed:22415931}.
FT                                /FTId=VAR_070543.
FT   MUTAGEN      78     78       N->Q: Abolishes glycosylation at this
FT                                site and causes moderate decrease in
FT                                activity. {ECO:0000269|PubMed:24125761}.
FT   MUTAGEN     282    282       N->Q: Abolishes glycosylation at this
FT                                site and causes substantial decrease in
FT                                activity and reduced substrate affinity.
FT                                {ECO:0000269|PubMed:24125761}.
FT   CONFLICT      3      3       R -> M (in Ref. 6; AA sequence).
FT                                {ECO:0000305}.
FT   CONFLICT     55     57       LHH -> VHI (in Ref. 1; AAA35551).
FT                                {ECO:0000305}.
SQ   SEQUENCE   399 AA;  45734 MW;  34F9CB717DD7417A CRC64;
     MGRKSLYLLI VGILIAYYIY TPLPDNVEEP WRMMWINAHL KTIQNLATFV ELLGLHHFMD
     SFKVVGSFDE VPPTSDENVT VTETKFNNIL VRVYVPKRKS EALRRGLFYI HGGGWCVGSA
     ALSGYDLLSR WTADRLDAVV VSTNYRLAPK YHFPIQFEDV YNALRWFLRK KVLAKYGVNP
     ERIGISGDSA GGNLAAAVTQ QLLDDPDVKI KLKIQSLIYP ALQPLDVDLP SYQENSNFLF
     LSKSLMVRFW SEYFTTDRSL EKAMLSRQHV PVESSHLFKF VNWSSLLPER FIKGHVYNNP
     NYGSSELAKK YPGFLDVRAA PLLADDNKLR GLPLTYVITC QYDLLRDDGL MYVTRLRNTG
     VQVTHNHVED GFHGAFSFLG LKISHRLINQ YIEWLKENL
//
